Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management

• Status: Completed
• Trial end date: 2018-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this study is to test whether a dipeptidyl peptidase-4 inhibitor, compared with a sulfonylurea, improves time in normal blood glucose range and reduces blood glucose variability. Blood glucose is measured using a continuous glucose monitoring device.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Washington
• Collaborators: Abbott; American Diabetes Association; Medtronic
• Treatments: Glipizide; Linagliptin

Criteria

Inclusion Criteria:

• Type 2 diabetes

• eGFR 15-59 mL/min/1.73 m2

• Hemoglobin A1c < 8%

• Age ≥ 18 years

• Current use of sulfonylurea

Exclusion Criteria:

• BMI > 40 kg/m2

• Actively using CGM for clinical care

• End stage renal disease needing dialysis

• Kidney transplant

• Pregnant or nursing

• Unable to provide informed consent